Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00195091 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00195091: Clinical Trial Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00195091 is a Phase 2 study that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00195091, a Phase 2 study, was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Patients with moderate to high risk primary breast cancer (Stage II with more than 4 lymph nodes involved with cancer) III or Stage IV (without evidence of disease) will take tetrathiomolybdate (TM) pills for two years. The objectives of the study are to: * Assess the safety and tolerability of tetrathiomolybdate in patients with breast cancer at high risk of tumor recurrence. * Observe the disease-free survival of patients in this trial. * Conduct background scientific experiments on tumor tissue and blood of patients in this study
Interventions
- DRUG Tetrathiomolybdate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2003-12 |
| Est. Completion | 2023-03-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00195091
The ClinicalTrials.gov registry entry for NCT00195091 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tetrathiomolybdate is the first listed.
NCT00195091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00195091 about?
NCT00195091 is a clinical study titled "Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer". Patients with moderate to high risk primary breast cancer (Stage II with more than 4 lymph nodes involved with cancer) III or Stage IV (without evidence of disease) will take tetrathiomolybdate (TM) pills for two years. The objectives of the study are to: * Assess the safety and tolerability of te...
What is the current status of trial NCT00195091?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2003-12. Estimated completion is 2023-03-02.
What interventions are being tested in trial NCT00195091?
The interventions under investigation include: Tetrathiomolybdate (DRUG).
Who is sponsoring clinical trial NCT00195091?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.